Table III.
Clinicopathological parameters and expression of XIAP and survivin in relation to pathological complete response (pCR)
| Parameter | non-pCR n (%) | pCR n (%) | P-value | Contingency coefficient | Tau b Kendall | |
|---|---|---|---|---|---|---|
| Age [years] | < 50 | 13 (22) | 8 (13) | 0.775 | 0.074 | –0.074 |
| ≥50 | 27 (45) | 12 (20) | ||||
| Tumour size | T1/T2 | 19 (32) | 11 (18) | 0.587 | 0.07 | –0.07 |
| T3/T4 | 21 (35) | 9 (15) | ||||
| TNM stage | IIB | 4 (7) | 2 (3) | 0.648 | 0.00 | 0.00 |
| III | 36 (60) | 18 (30) | ||||
| Histological type | NST | 36 (60) | 18 (30) | 0.648 | 0.00 | 0.00 |
| LOB | 4 (7) | 2 (3) | ||||
| Histological grade | G2 | 20 (33) | 10 (17) | 1.000 | 0.00 | 0.00 |
| G3 | 20 (33) | 10 (17) | ||||
| ER status | Negative | 19 (32) | 11 (18) | 0.587 | 0.07 | –0.07 |
| Positive | 21 (35) | 9 (15) | ||||
| PR status | Negative | 21 (35) | 11 (18) | 0.856 | 0.02 | –0.02 |
| Positive | 19 (32) | 9 (15) | ||||
| HER-2 status | Negative | 18 (30) | 16 (27) | 0.021 | 0.32 | –0.33 |
| Positive | 22 (37) | 4 (7) | ||||
| Triple negative | No | 29 (48) | 12 (20) | 0.331 | 0.13 | 0.13 |
| Yes | 11 (18) | 8 (13) | ||||
| XIAP expression | Low/intermediate | 27 (45) | 19 (32) | 0.040 | 0.29 | –0.31 |
| High | 13 (22) | 1 (2) | ||||
| Survivin expression | Low/intermediate | 20 (33) | 20 (33) | < 0.001 | 0.45 | 0.50 |
| High | 20 (33) | 0 | ||||
NST – invasive carcinoma of no special type, LOB – invasive lobular carcinoma, ER – oestrogen receptor, PR – progesterone receptor, HER-2 – human epidermal growth factor receptor type 2, pCR – pathological complete response, non-pCR – non-pathological complete response.